A 46-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY WITH A 6-WEEK RANDOMIZED-WITHDRAWAL PERIOD TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS (NCTNCT03420781) - Patient Guide & Enrollment Help